Paper Details

  1. Home
  2. Paper Details

Substance P receptor blocker, aprepitant, inhibited cutaneous and other neurogenic inflammation side effects of the EGFR1-TKI, erlotinib.

Author: ChmielinskaJoanna J, KramerJay H, MakI-Tong, SpurneyChristopher F, WeglickiWilliam B

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the effects of aprepitant on erlotinib-induced adverse events in rats. Aprepitant significantly mitigated the systemic and cutaneous adverse effects of erlotinib, suggesting its potential as a novel therapy for managing erlotinib side effects.
Paper Details　
Original Abstract of the Article :
Cutaneous changes like rash and hair loss, as well as other neurogenic inflammation side effects, occur frequently during anticancer treatment with the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), erlotinib. These adverse events may be so severe that they impair the patient...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s11010-019-03677-7

データ提供：米国国立医学図書館（NLM）

Aprepitant: A Potential Therapy for Erlotinib-Induced Skin Side Effects

Erlotinib, a medication used in cancer treatment, can cause a variety of side effects, including skin rash and hair loss. This research explores the potential of aprepitant, a substance P receptor blocker, to mitigate these side effects. The study uses a rat model to investigate the impact of aprepitant on erlotinib-induced cutaneous and neurogenic inflammation. This research is important because it may lead to improved patient outcomes and reduce the burden of side effects associated with cancer treatment.

Aprepitant: A Potential Solution for Erlotinib Side Effects

The study found that aprepitant effectively mitigated the adverse cutaneous and neurogenic inflammatory side effects of erlotinib in rats. The researchers observed a significant reduction in skin lesions, hair loss, and inflammation. These results suggest that aprepitant may be a valuable therapeutic option for reducing the side effects of erlotinib treatment in humans.

Navigating Cancer Treatment Side Effects

This research highlights the importance of managing the side effects of cancer treatment. It encourages patients to discuss their concerns with healthcare providers and explore potential strategies to minimize these side effects. This research also underscores the need for continued research to develop safer and more effective therapies for cancer patients.

Dr. Camel's Conclusion

This study provides promising evidence for the use of aprepitant in mitigating the side effects of erlotinib treatment. It offers a potential solution to a common problem faced by cancer patients, potentially improving their quality of life during treatment. This research emphasizes the need for continued research and development to find safer and more effective treatments for cancer.

Date :
  1. Date Completed 2020-03-19
  2. Date Revised 2020-03-19
Further Info :

Pubmed ID

31853800

DOI: Digital Object Identifier

10.1007/s11010-019-03677-7

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.